TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female.~* Aged 18-55 years (both inclusive) at the time of signing informed consent.~* Body mass index (BMI) between 23.0 and 29.9 kilogram per meter\^2 (kg/m\^2) (both inclusive) at screening.~Exclusion Criteria:~* Known or suspected hypersensitivity to trial products or related products, or to electrocardiogram (ECG) electrodes.~* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.~* History of seizures, epilepsy, repeated syncopes, cardiac arrest, cardiac arrhythmia or Torsades de Pointes (TdP), 2nd or 3rd degree atrioventricular (A-V) block or structural heart disease.~* Family history of long QT syndrome (either objectively diagnosed or suggested by sudden death due to cardiac causes before the age of 50 of a 1st degree relative).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cagrilintide (Arm 1) (Type: EXPERIMENTAL): Participants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.
- Cagrilintide Placebo (Arm 2A) (Type: ACTIVE_COMPARATOR): Participants will receive cagrilintide placebo subcutaenously once weekly. In addition, a single dose of moxifloxacin active prior to initiation of treatment and a single dose of moxifloxacin placebo at the end of the treatment period will be administered orally.
- Cagrilintide Placebo (Arm 2B) (Type: ACTIVE_COMPARATOR): Participants will receive cagrilintide placebo subcutaneously once weekly. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose of moxifloxacin active at the end of the treatment period will be administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must understand and voluntarily sign an informed consent form.~2. Older than 18 years old at the time of signing consent.~3. Meet the diagnostic criteria of POEM syndrome.~4. Must be cytotoxic treatment naive. However, previous or existing corticosteroid (prednisone or dexamethasone) or intravenous immunoglobin (IVIG) therapy is allowed.~5. Women of childbearing potential must understand that the study medication could have a potential teratogenic risk. They should undergo complete contraception during the study period.~6. Male subjects must agree to use condoms throughout study drug therapy.~Exclusion Criteria:~1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~2. Pregnant or lactating females.~3. Any of the following laboratory abnormalities:~   Absolute neutrophil count(ANC) of\<1.0×10E9 cell/L. Platelet count\<50×10E9 cell/L. Renal failure requiring dialysis. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times of the normal upper limit.~4. Prior history of malignancies, but not including basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and T1a or T1b prostate cancer.~5. Known hypersensitivity or prior history of uncontrollable side effects to dexamethasone therapy.~6. Prior use of cytotoxic drugs.~7. Subjects who are unable or unwilling to undergo antithrombotic therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide, dexamethasone (Type: EXPERIMENTAL): Lenalidomide 10mg qd d1-21 \& dexamethasone 40mg qw d1,8,15,22

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Parkinson's Disease or Parkinson Plus Syndrome~* Subject is a male or female between the age of 50 and 95~* Subject will write the informed consent~Exclusion Criteria:~* History of stroke or/and trauma~* Signs of cerebrovascular pathology~* Brain tumor~* Severe unrelated neurological or physical disease

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- PD Parkinson´s Disrease (Type: None): We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
- AP Atypical Parkinsonism (Type: None): with neurodegenerative disease (proteinopathies) and secondary AP.
- Control group (Type: None): Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: mHealth for Self-care of Heart Failure in Uganda

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* UHI patient presenting for routine or urgent outpatient visit~* Currently living in Uganda and not planning to travel abroad for six months~* Age \>=18 years~* Symptomatic heart failure (New York Heart Association Class II or III and left ventricular ejection fraction of 45% or less)~* Access to a mobile phone~* Basic reading skills in English, Luganda, and/or Runyankole~Exclusion Criteria:~* Life expectancy \< six months~* Active medical condition requiring hospitalization, such as cardiac ischemia (acute electrocardiographic changes and/or positive biomarkers, if available), syncope, or significant fluid overload~* Pregnancy~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- mHealth (Type: OTHER): Heart failure patients enrolled in the mHealth program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with type 2 diabetes mellitus~* Have been taking metformin and/or pioglitazone~* Have received treatment with basal insulin glargine, injected once a day, for greater than or equal to 90 days~* Have glycosylated hemoglobin A1c (HbA1c) concentration between greater than or equal to 7.5% and less than or equal to 10.5~* Have a fasting plasma glucose concentration of less than or equal to 6.7 millimoles per liter \[mmol/L, less than or equal to 121 milligrams per deciliter (mg/dL)\], or greater than 6.7 mmol/L (greater than 121 mg/dL) if the investigator considers that further titration of basal insulin glargine is not possible for safety reasons~* Not pregnant or breastfeeding~Exclusion Criteria:~* Have Type 1 Diabetes~* Their stable dose of pioglitazone is greater than the maximum dose approved for use in combination with insulin in their country~* Have a body mass index (BMI) greater than 45 kilograms per square meter (kg/m2).~* Have a history of scheduled mealtime (prandial) insulin use within 12 weeks of the screening visit and the total duration of the prandial insulin treatment was greater than 2 weeks~* Have had more than one episode of severe hypoglycaemia within 24 weeks prior to entry into the study~* Have cardiac disease with a functional status that is Class III or IV~* Have a history of renal or liver disease~* Have had a blood transfusion or have a blood disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin lispro low mixture (LM) (Type: EXPERIMENTAL): Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
- Insulin glargine+insulin lispro (Type: ACTIVE_COMPARATOR): Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cetuximab to Treat Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced or metastatic adenocarcinoma of the stomach~* ECOG performance scale ≤ 1~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Adequate hepatic, renal, heart, and hematologic functions (platelets\>80 × 109/L, neutrophil\>2.0 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper limit of normal(ULN), and serum transaminase≤2.5×the ULN)~Exclusion Criteria:~* Pregnant or lactating women~* Concurrent cancer~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* Neuropathy, brain, or leptomeningeal involvement~* Uncontrolled significant comorbid conditions and previous radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): administer cetuximab in combination with modified FOLFIRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent~* Men and women ≥ 19 years of age~* Subject who has one of 3 conditions classified by Cardiovascular Risk Factors, 10-Year Risk, Blood Pressure, LDL-C, TG, Coronary Artery Disease and Equivalent~Exclusion Criteria:~* Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.~* Other exclusions applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YH16410 (Type: EXPERIMENTAL): PO, Once Daily, 8 weeks
- Rosuvastatin (Type: ACTIVE_COMPARATOR): PO, Once Daily, 8 weeks
- Telmisartan (Type: ACTIVE_COMPARATOR): PO, Once Daily, 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): PO, Once Daily, 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor or B-cell lymphoma and meets at least 1 of the following criteria:~  * Disease progression despite standard therapies~ * No standard therapies are available or such therapies are not anticipated to result in a durable response~ * Standard therapies are considered unsuitable or have been refused~* Able to take oral medications~* Life expectancy \> 12 weeks~* For the expansion cohort of the study, all subjects must be confirmed to be positive for ALK gene abnormalities~* Subjects with stable brain metastasis will be allowed~Exclusion Criteria:~* Active central nervous system (CNS) metastases or leptomeningeal involvement as assessed through medical history review and physical examination (dose escalation subjects only)~* Known history of a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)~* Known hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection~* Cardiac arrhythmias \> Grade 1 using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03~* Class 3 or 4 New York Heart Association congestive heart failure, acute coronary syndrome, myocardial infarction or cerebrovascular accident within 6 months prior to Cycle 1, Day 1~* Inadequate bone marrow, renal, and/or hepatic function~* Confirmed active peptic ulcer disease or history of gastrointestinal bleeding within the past 3 months~* Known history of long QT syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3026 (Type: EXPERIMENTAL): Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Attention & Memory Impairments in Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women ages 45 to 60 will be eligible for this study if they:~* Are within 5 years of their last menstrual period;~* Are able to give written informed consent;~* Must have clear urine toxicology screen upon recruitment;~* Are fluent in written and spoken English;~* Must have negative urine pregnancy test if still menstruating.~Exclusion Criteria:~* History of seizures;~* History of cardiac disease including known cardiac defect or conduction abnormality;~* Abnormal electrocardiogram during screening;~* Use of estrogen therapy within previous 6 months;~* Current pregnancy or planning to become pregnant.~* Presence of a contraindication to treatment with stimulant medication; this would include the presence of hypertension, coronary disease, atrial fibrillation, and arrhythmia.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine, then placebo (Type: EXPERIMENTAL): Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
- Placebo, then Lisdexamfetamine (Type: EXPERIMENTAL): Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous Paracetamol in Manament of Labour Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primiparous~* aged 18-35 years,~* Term live singleton pregnancy,~* Vertex presentation,~* Spontaneous onset of labor at term 37-42 weeks gestation,~* In active phase of of 1st stage of labour (cervix dilatation 3- 4 cm).~Exclusion Criteria:~Clinical evidence of cephalopelvic disproportion~* Use of any kind of analgesia prior to study~* Any medical disorder during pregnancy (liver or kidney impairment)~* Induction of labor, Intrauterine fetal death~* Evidence of fetal distress~* Antenatal diagnosis of congenital malformation~* Previous history of hypersensitivity to either drug~* Extremes of age (i.e. below 18 or above 35)~* Multiple pregnancies~* Cervical dilatation more than 6 cm.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- paracetamol group (Type: ACTIVE_COMPARATOR): Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].
- pethidine group (Type: ACTIVE_COMPARATOR): Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be ≥12 years of age.~* Have a confirmed diagnosis of Hereditary Angioedema.~Exclusion Criteria:~* Receipt of any C1 inhibitor (C1 INH) therapy or any blood products for treatment or prevention of an angioedema attack within 7 days before the first dose of study drug.~* Be receiving prophylactic intravenous CINRYZE that exceeds 1000 units every 3 or 4 days (maximum weekly dose 2000 units).~* Have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 7 days prior to the first dose of study drug.~* If female, have started taking or changed the dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug.~* History of allergic reaction to C1 INH products, including CINRYZE or other blood products.~* History of abnormal blood clotting.~* Have a known allergy to hyaluronidase or any other ingredient in the study formulation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2 (Type: EXPERIMENTAL): SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
- SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1 (Type: EXPERIMENTAL): SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Mechanisms of Manual Therapy in the Treatment of Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* currently experiencing low back pain which does not extend below the knees~* rate the low back pain as a minimum of 4/10 at worst over the past 24 hours~* appropriate for conservative management of low back pain~* english speaking~Exclusion Criteria:~* surgery to the low back over the past 6 months~* systemic disease known to effect sensation~* other chronic pain condition unrelated to low back pain~* fracture as a cause of low back pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- spinal manipulation (Type: ACTIVE_COMPARATOR): a spinal manipulation known to be effective in the treatment of low back pain for some individuals
- sham spinal manipulation (Type: PLACEBO_COMPARATOR): a sham spinal manipulation intended to mimic the studied spinal manipulation
- natural history (Type: NO_INTERVENTION): No intervention is provided to participants in this arm of the study
- Enhanced sham spinal manipulation (Type: PLACEBO_COMPARATOR): a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete